Stereochemistry & Drug Action: Chirality effects in ADME and pharmacology MCQs With Answer

Stereochemistry & Drug Action: Chirality effects in ADME and pharmacology MCQs With Answer

Introduction: This quiz collection explores how chirality influences drug behavior and therapeutic outcomes, essential for M.Pharm students studying Advanced Medicinal Chemistry. Focusing on stereochemistry in absorption, distribution, metabolism, excretion (ADME) and pharmacodynamics, the questions probe stereoselective receptor binding, enantiomer-specific toxicity, chiral inversion, metabolism by stereoselective enzymes, and regulatory aspects of chiral drugs. These MCQs are designed to deepen understanding beyond basics, linking molecular stereochemistry to real-world drug development decisions such as chiral switches, racemate vs single-enantiomer formulations, and analytical challenges. Answers are provided to reinforce learning and encourage critical thinking about chirality in drug action.

Q1. How does chirality most commonly influence a drug’s pharmacodynamic profile?

• Both enantiomers always have identical receptor affinities
• One enantiomer may have higher affinity and efficacy at the target receptor than the other
• Chirality only affects pharmacokinetics, not pharmacodynamics
• Enantiomers are always metabolized to the same active metabolite

Correct Answer: One enantiomer may have higher affinity and efficacy at the target receptor than the other

Q2. Which stereochemical phenomenon describes the in vivo conversion of one enantiomer into its mirror image?

• Racemization
• Enantioselective binding
• Chiral inversion
• Atropisomerism

Correct Answer: Chiral inversion

Q3. Why can racemic drugs lead to different safety profiles compared with single-enantiomer drugs?

• Racemates have twice the potency of single enantiomers
• One enantiomer in a racemate may cause adverse effects or drug interactions absent in the other
• Racemates are always less soluble than single enantiomers
• There is no regulatory difference between racemates and enantiopure drugs

Correct Answer: One enantiomer in a racemate may cause adverse effects or drug interactions absent in the other

Q4. Which analytical technique is most commonly used to separate and quantify enantiomers in biological samples?

• Normal-phase TLC
• Achiral HPLC with UV detection
• Chiral chromatography (e.g., chiral HPLC)
• Gasometry

Correct Answer: Chiral chromatography (e.g., chiral HPLC)

Q5. What is atropisomerism and when is it pharmacologically relevant?

• It is enantiomerism due to a stereogenic center; relevant only for small molecules
• It is stereoisomerism arising from hindered rotation about a bond; relevant when the rotational barrier is high enough to isolate stable conformers
• It is racemization under acidic conditions; relevant only during formulation
• It describes diastereomeric pairs formed during metabolism

Correct Answer: It is stereoisomerism arising from hindered rotation about a bond; relevant when the rotational barrier is high enough to isolate stable conformers

Q6. Which statement best explains stereoselective metabolism?

• All metabolic enzymes act equally on both enantiomers
• Metabolic enzymes may preferentially metabolize one enantiomer, leading to differing clearance rates
• Stereoselective metabolism always results in toxic metabolites
• Stereoselective metabolism only occurs for chiral amino acids

Correct Answer: Metabolic enzymes may preferentially metabolize one enantiomer, leading to differing clearance rates

Q7. In the context of stereochemistry, what is a “chiral switch”?

• Converting a chiral center into an achiral center chemically
• Developing and marketing the single active enantiomer of a previously marketed racemate
• Changing the chirality of a drug during manufacturing to save costs
• Switching from an oral to an injectable formulation of a racemate

Correct Answer: Developing and marketing the single active enantiomer of a previously marketed racemate

Q8. Which ADME parameter is LEAST likely to be influenced by stereochemistry?

• Receptor binding affinity (pharmacodynamics)
• Plasma protein binding
• Volume of distribution
• Atomic weight of the drug molecule

Correct Answer: Atomic weight of the drug molecule

Q9. A drug exhibits enantioselective plasma protein binding. What is a likely consequence?

• Both enantiomers will have identical free (unbound) concentrations
• The enantiomer with greater protein binding will have a lower free fraction and potentially lower pharmacologic effect
• Protein binding does not affect pharmacologic effect
• Enhanced renal clearance of the more highly protein-bound enantiomer

Correct Answer: The enantiomer with greater protein binding will have a lower free fraction and potentially lower pharmacologic effect

Q10. Which enzyme family is most commonly associated with stereoselective oxidative metabolism of chiral drugs?

• Cytochrome P450 enzymes (CYPs)
• Kinases
• Peptidases
• DNA polymerases

Correct Answer: Cytochrome P450 enzymes (CYPs)

Q11. When designing an enantioselective bioanalytical method, which internal standard is most appropriate?

• An achiral compound unrelated to the analyte
• A racemate of the analyte
• The stable isotopically labeled enantiomer of the target analyte (if available)
• Any compound with similar polarity

Correct Answer: The stable isotopically labeled enantiomer of the target analyte (if available)

Q12. Which regulatory consideration is specifically relevant when developing a single-enantiomer drug derived from a racemate?

• Single-enantiomer drugs never require additional clinical data
• Comparative pharmacokinetic and safety data vs the racemate are often required
• Regulators prohibit approval of single enantiomers
• No stereochemical characterization is necessary

Correct Answer: Comparative pharmacokinetic and safety data vs the racemate are often required

Q13. Which term describes two stereoisomers that are non-superimposable mirror images?

• Enantiomers
• Conformers
• Regioisomers
• Meso compounds

Correct Answer: Enantiomers

Q14. A chiral drug shows much greater CNS penetration for the R-enantiomer than the S-enantiomer. Which factor could explain this?

• Enantioselective active transport across the blood–brain barrier
• The R-enantiomer has a lower molecular weight
• Both enantiomers must penetrate equally due to passive diffusion
• Stereochemistry does not affect BBB penetration

Correct Answer: Enantioselective active transport across the blood–brain barrier

Q15. Which is a common consequence of stereoselective first-pass metabolism?

• Equal oral bioavailability of both enantiomers
• Different oral bioavailability and systemic exposure for each enantiomer
• Complete absorption with no stereochemical effects
• First-pass metabolism affects only achiral drugs

Correct Answer: Different oral bioavailability and systemic exposure for each enantiomer

Q16. What is the main pharmacological concern when an inactive enantiomer is present in high concentrations?

• Inactive enantiomers always enhance efficacy
• They can compete for metabolism or transporters and alter the active enantiomer’s PK/PD
• Inactive enantiomers are completely inert in biological systems
• High concentrations of inactive enantiomers increase chemical stability only

Correct Answer: They can compete for metabolism or transporters and alter the active enantiomer’s PK/PD

Q17. Which statement about diastereomers is TRUE?

• They are mirror images of each other
• They have identical physical properties and biological activities
• They are stereoisomers that are not mirror images and can show different physical and biological properties
• They always interconvert rapidly at room temperature

Correct Answer: They are stereoisomers that are not mirror images and can show different physical and biological properties

Q18. Which experimental observation would most strongly indicate stereoselective receptor activation?

• Both enantiomers produce identical dose-response curves in a receptor assay
• One enantiomer shows a lower EC50 and higher maximal response than the other
• Neither enantiomer binds to the receptor
• Both enantiomers are metabolized equally by liver enzymes

Correct Answer: One enantiomer shows a lower EC50 and higher maximal response than the other

Q19. How can chiral inversion complicate therapeutic monitoring of a drug?

• It leads to a stable single enantiomer in plasma simplifying monitoring
• Conversion of the administered enantiomer to its mirror image can change pharmacologic activity over time, complicating interpretation of plasma levels
• Chiral inversion only occurs in vitro and is irrelevant clinically
• It prevents any metabolism from occurring

Correct Answer: Conversion of the administered enantiomer to its mirror image can change pharmacologic activity over time, complicating interpretation of plasma levels

Q20. When is development of a single-enantiomer product most scientifically justified?

• When the other enantiomer is pharmacologically inert and adds no risk or interaction
• When one enantiomer has clearly superior efficacy or a better safety profile than the racemate
• Only when the racemate is cheaper to produce
• Single-enantiomer development is never justified

Correct Answer: When one enantiomer has clearly superior efficacy or a better safety profile than the racemate

Download